In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Retinal implant start-up Pixium completes €34.5mm IPO in France

Executive Summary

Pixium Vision (sensory neuromodulation to restore vision) raised €34.5mm ($47mm) in its IPO on Euronext Paris. The company sold 4.2mm shares (including full exercise of the extension clause; more than the 3.6mm planned) for €8.28, the bottom end of its €8.28-10.12 price range. Bpifrance Participations bought €8.5mm IPO shares (and adds a board member to Pixium), and existing investors Sofinnova, Abingworth, Omnes Capital, Innobio, and Seventure purchased €8.5mm.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies